Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade

Figure 1

Overall and cancer-specific survival in the responders and nonresponders.

(a) Overall survival in PSA decline (any)

(b) Cancer-specific survival in PSA decline (any)

(c) Overall survival in PSA decline (40%)

(d) Cancer-specific survival in PSA decline (40%)

(e) Overall survival in patients with PSA decline (50%)

(f) Cancer-specific survival in patients with PSA decline (50%)